Understanding how certain proteins affect blood clotting issues caused by heparin.
Official title: The role of proteoglycans in Heparin-induced thrombocytopenia: Implications for pathophysiology, diagnosis and treatment
Funded at Mayo Clinic Rochester · NIH-11010341 · Data updated 2026-11-12
This study is looking at how certain proteins in your blood might play a role in heparin-induced thrombocytopenia (HIT), a serious condition that can happen if you’re treated with heparin, and it aims to find out how different factors like age, sex, and ethnicity affect this condition to help improve tests and treatments for patients at risk.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $165,780 |
| NIH project number | 5K99HL171911-02 |
| Project ID | NIH-11010341 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients who are receiving heparin and may be at risk for developing heparin-induced thrombocytopenia.
✕Less likely to help
Patients who are not receiving heparin or those who have not experienced any adverse reactions to heparin are unlikely to benefit from this research.
What this research studies
This research investigates the role of specific proteins called proteoglycans in the development of heparin-induced thrombocytopenia (HIT), a serious condition that can occur in patients receiving heparin. The study aims to identify the platelet components that interact with heparin and trigger the immune response leading to HIT. By analyzing differences in these components based on factors like age, sex, and ethnicity, the research seeks to improve diagnostic tests and treatment strategies for affected patients. This could lead to better risk stratification and targeted therapies for those at higher risk of developing HIT.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients suffering from heparin-induced thrombocytopenia.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for HIT, but this study aims to explore novel aspects of the condition that have not been extensively tested.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Kanack, Adam J — Mayo Clinic Rochester
- Study coordinator: Kanack, Adam J
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.